Literature DB >> 10873551

Importance of local production of endothelin-1 and of the ET(B)Receptor in the regulation of pulmonary vascular tone.

J Dupuis1, J F Jasmin, S Prié, P Cernacek.   

Abstract

Interaction between locally released endothelin-1 (ET-1) and the endothelial ET(B)receptor could modulate pulmonary vascular tone. We evaluated pulmonary ET-1 clearance and ET-1-ET(B)receptor interaction in the modulation of pulmonary vascular tone. Controls and rats with Monocrotaline (MCT)-induced pulmonary hypertension (PH) were studied. Lungs were isolated and perfused under constant pressure. The effect of the selective ET(B)antagonist BQ-788 (10(-12)-10(-8)mole) on perfusion flow rate and(125)I-ET-1 extraction was determined. Baseline(125)I-ET-1 extraction was reduced from 62+/-5% in controls to 49+/-10% in PH (P=0.012). BQ-788 inhibited extraction with a higher half-inhibitory dose in the MCT group (-Log ID(50)= 8.9+/-0.4 vs. 9.5+/-0.1, P=0.03). BQ-788 induced a mild reduction in perfusion flow rate of 0.7+/-0.3 ml/min in controls. In the MCT group, this occurred at a lower dose and was more pronounced with a maximal reduction of 3.3+/-0.7 ml/min (P<0.01 vs. control). ET-1 was undetectable in the effluent at baseline but was present in similar concentrations in both groups after ET(B)blockade. Addition of 2 pg/ml ET-1 to lung perfusate did not modify pulmonary ET-1 clearance or the effect of BQ788 on perfusion flow rate in control lungs. In normal rat lungs, the ET(B)receptor plays a minor regulatory role on vascular tone. In MCT hypertension however, despite a reduction in ET(B)mediated extraction, luminal production of ET-1 attenuates the increase in pulmonary vascular tone. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10873551     DOI: 10.1006/pupt.2000.0242

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  9 in total

Review 1.  Role of the endothelin axis and its antagonists in the treatment of cancer.

Authors:  A Bagnato; M Loizidou; B R Pflug; J Curwen; J Growcott
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

Review 2.  Vascular endothelin receptor type B: structure, function and dysregulation in vascular disease.

Authors:  Marc Q Mazzuca; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2012-03-30       Impact factor: 5.858

3.  Endothelin receptor polymorphisms in the cardiovascular system: potential implications for therapy and screening.

Authors:  Luise Holzhauser; Ronald Zolty
Journal:  Heart Fail Rev       Date:  2014-11       Impact factor: 4.214

Review 4.  The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?

Authors:  N S Kirkby; P W F Hadoke; A J Bagnall; D J Webb
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

5.  Change in pharmacological effect of endothelin receptor antagonists in rats with pulmonary hypertension: role of ETB-receptor expression levels.

Authors:  Stéphanie Sauvageau; Eric Thorin; Louis Villeneuve; Jocelyn Dupuis
Journal:  Pulm Pharmacol Ther       Date:  2009-08       Impact factor: 3.410

6.  Endothelins contribute towards nociception induced by antigen in ovalbumin-sensitised mice.

Authors:  Anna P Piovezan; Pedro D'Orléans-Juste; Monica Frighetto; Glória E P Souza; Maria G M O Henriques; Giles A Rae
Journal:  Br J Pharmacol       Date:  2004-01-26       Impact factor: 8.739

7.  Endothelin-3-dependent pulmonary vasoconstriction in monocrotaline-induced pulmonary arterial hypertension.

Authors:  Stéphanie Sauvageau; Eric Thorin; Louis Villeneuve; Jocelyn Dupuis
Journal:  Peptides       Date:  2008-08-15       Impact factor: 3.750

Review 8.  Pulmonary hypertension and cardiac anesthesia: Anesthesiologist's perspective.

Authors:  Manjula Sudeep Sarkar; Pushkar M Desai
Journal:  Ann Card Anaesth       Date:  2018 Apr-Jun

Review 9.  Therapeutic Challenges And Advances In The Management Of Systemic Sclerosis-Related Pulmonary Arterial Hypertension (SSc-PAH).

Authors:  Rahul G Argula; Celine Ward; Carol Feghali-Bostwick
Journal:  Ther Clin Risk Manag       Date:  2019-12-13       Impact factor: 2.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.